Wanbury targets FY27 formulations profitability from launches
Key highlights
- Wanbury reported formulations revenue of Rs 22 crore in Q2FY27, compared with Rs 21 crore in Q2FY26.
- Wanbury reported Rs 39 crore of formulations revenue in H1FY27 versus Rs 41 crore in H1FY26.
- Wanbury targets formulations break-even in FY26 and sustainable profitability from FY27.
- Wanbury’s largest formulations brand accounts for 41% of formulations revenue.
powered by IRIS

Wanbury Limited targets sustainable formulations profitability from FY27 by shifting launches into chronic and speciality therapies, after setting an FY26 break-even objective; the business reported Rs 22 crore of revenue in Q2FY27, 5% above Rs 21 crore in Q2FY26, according to the presentation.
Know Wanbury inside out
Results, valuation, peers and who's buying, in one view.
What is Wanbury rebuilding in its formulations business?
Wanbury is rebuilding a branded formulations franchise focused on acute therapy, with more than 10 brands, a field force of more than 300 people and engagement with more than 30,000 doctors. The formulations business began in 1995 with the acquisition of Wander Ltd, formerly a division of Sandoz, giving Wanbury more than three decades of heritage in this business.
Wanbury’s current portfolio spans anti-cold and cough, anti-infective, anti-inflammatory, analgesic, antipyretic, orthopaedic and constipation treatments. It also includes protein supplements, multivitamins and multimineral supplements, while the presentation identifies 100% acute therapy as the current portfolio mix before the planned shift into chronic and speciality categories.
Wanbury uses a fully outsourced manufacturing model for formulations rather than disclosing a formulations manufacturing-capacity investment programme. The company says the model provides scalability and flexibility, while a dedicated business-excellence team focuses on brand building and distribution; the current network includes 17 clearing and forwarding, or C&F, agents and more than 1,800 distributors.
How has Wanbury formulations revenue changed?
Wanbury reported formulations revenue of Rs 22 crore in Q2FY27, compared with Rs 21 crore in Q2FY26, and the presentation describes the movement as 5% year-on-year growth. Revenue also rose sequentially from Rs 17 crore in Q1FY27 to Rs 22 crore in Q2FY27, a Rs 5 crore increase during the first half.
Wanbury reported Rs 39 crore of formulations revenue for H1FY27, compared with Rs 41 crore in H1FY26. The presentation labels H1FY27 formulations growth as 4% year on year, but the displayed figures show the later first-half revenue was Rs 2 crore below the prior-year period; H1 means the first half of the financial year.
The formulations revenue share was 13% in FY22, fell to 10% in FY23, recovered to 11% in FY24 and was 12% in both FY25 and FY26. This shows that the unit’s disclosed revenue share improved by 2 percentage points from FY23 to FY26, but remained 1 percentage point below the FY22 level.
Got a follow-up? Ask IRIS
Which products will Wanbury launch beyond acute therapies?
Wanbury plans to transition its portfolio from acute therapeutics towards speciality and chronic segments through new launches. The stated upcoming therapeutic priorities are paediatrics, dermatology, cardiology and diabetes, with cardiology and diabetes intended to add chronic and speciality products and improve portfolio diversity.
Wanbury says paediatrics and dermatology offer a better right-to-win through existing brand equity with paediatricians. It also plans to build a presence across gynaecology, paediatrics, cardiology, orthopaedics and surgery, identified in the presentation as GYN, PED, CP, ORTHO and SUR speciality segments.
The latest disclosed brand launch was C RED, an iron supplement introduced in FY25. The existing portfolio includes Coriminic for anti-cold and cough, Chymonac for pain, inflammation and muscular spasm, RabiPlus for antacids and anti-ulcerants, and Senasoft, a herbal laxative.
Wanbury also lists Nufuture, a protein supplement; ADTROL, a calcium supplement for osteoporosis and bone health; WANBURY C RED, a nutritional supplement; and Zeva, a multivitamin supplement. Its number-one brand accounts for 41% of formulations revenue, while the second and third brands account for 10% and 7%, respectively, and all other brands account for 42%.
How does Wanbury plan to reach formulations profitability?
Wanbury’s stated objective was to achieve formulations profitability break-even in FY26 through better scale and cost-management efforts, followed by sustainable profitability from FY27. These are management objectives in the presentation, not reported formulations profit figures, as the disclosed segment metrics are revenue figures including Rs 39 crore for H1FY27.
Wanbury’s FY27 execution plan is to scale top brands, launch new therapies and increase front-line doctor engagement. The company already reports engagement with more than 30,000 doctors through a field force of more than 300 people, and it plans to expand into newer regions while increasing field force in existing regions.
The revenue pattern gives context for that plan. Q2FY27 formulations revenue of Rs 22 crore was above both Rs 21 crore in Q2FY26 and Rs 17 crore in Q1FY27, but H1FY27 revenue of Rs 39 crore was below Rs 41 crore in H1FY26. Wanbury has not disclosed a separate formulations earnings amount, margin target or timetable for individual chronic and speciality launches.
Conclusion
Wanbury’s formulations plan is a commercial rebuild rather than a disclosed manufacturing expansion. It retains outsourced production while using more than 1,800 distributors, more than 300 field-force personnel and established brands to support a move from a 100% acute-therapy portfolio into chronic and speciality treatments.
The next item to watch is whether Wanbury converts its FY26 break-even objective into the sustainable FY27 profitability it has outlined. The presentation identifies geographic expansion, additional field-force deployment, higher doctor engagement and launches in cardiology, diabetes, paediatrics and dermatology as the disclosed execution measures, following Rs 39 crore of H1FY27 formulations revenue.


